866-997-4948(US-Canada Toll Free)

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 84 Pages

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vancomycin-Resistant Enterococcus faecium Infections - Overview 8
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 25
Alchemia Ltd 25
Aphios Corp 25
C3J Therapeutics Inc 25
Helix BioMedix Inc 26
Hsiri Therapeutics LLC 26
LegoChem Biosciences Inc 27
MGB Biopharma Ltd 27
MicuRx Pharmaceuticals Inc 27
Nanotherapeutics Inc 28
NovoBiotic Pharmaceuticals LLC 28
Oragenics Inc 29
Ovensa Inc 29
Rebiotix Inc 29
Sealife PHARMA GMBH 30
Wockhardt Ltd 30
Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles 32
AM-218 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BDM-I - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
chrysophaentin - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
closthioamide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
contezolid acefosamil - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
HB-1345 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
HT-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
HT-02 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
IBN-1 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
LCB-010371 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Marinus - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MGBBP-3 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
MRX-I - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NAI-107 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NAI-108 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
NAI-603 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
OG-253 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ramoplanin - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
RBX-2660 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
SLP-0901 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SLP-0904 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SLP-0905 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecule for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Infections - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules for Bacterial Infections - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Target Bacterial Cell Wall for Vancomycin-Resistant Enterococcus faecium and Staphylococcus aureus Infections - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Teixobactin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
WCK-4086 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 77
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 78
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 79
Featured News & Press Releases 79
Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4 79
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 79
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 80
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 80
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 81
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Stage and Target, H2 2017 18
Number of Products by Stage and Mechanism of Action, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Ltd, H2 2017 25
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H2 2017 25
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3J Therapeutics Inc, H2 2017 26
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H2 2017 26
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H2 2017 26
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, H2 2017 27
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H2 2017 27
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H2 2017 28
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics Inc, H2 2017 28
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017 28
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H2 2017 29
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H2 2017 29
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, H2 2017 30
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2017 30
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H2 2017 31
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2017 77
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H2 2017 78

List of Figures
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Number of Products under Development by Universities/Institutes, H2 2017 13
Number of Products by Top 10 Targets, H2 2017 17
Number of Products by Stage and Top 10 Targets, H2 2017 17
Number of Products by Top 10 Mechanism of Actions, H2 2017 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 19
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Molecule Types, H2 2017 23
Number of Products by Stage and Molecule Types, H2 2017 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *